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Abstract
Background: Voriconazole Resistance (VRC-R) in Aspergillus flavus isolates impacts the management of aspergillosis, since azoles are the first choice for prophylaxis and therapy. However, to the best of our knowledge, the mechanisms underlying voriconazole resistance are poorly understood.
Objectives: The present study was designed to evaluate mRNA expression levels of cyp51A and mdr1 genes in voriconazole resistant A. flavus by a Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) technique.
Materials and Methods: Five A. flavus isolates with resistance to VRC were examined by a RT-PCR approach.
Results: Four out of five isolates revealed cyp51A and mdr1 mRNA overexpression. Interestingly, the isolate, which was negative for cyp51A and mdr1 mRNA expression showed a high voriconazole Minimum Inhibitory Concentration (MIC). Furthermore, a computational-based analysis predicted that voriconazole resistance could be mediated through cooperation with a network protein interaction.
Conclusions: Our experimental and in silico findings may provide new insight in the complex molecular pathways of drug resistance and also could assist design an efficient therapeutic strategy for aspergillosis treatment.
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1. BackgroundInvasive Aspergillosis (IA) is widespread in immunocom-promised individuals and has become a great concern for the management of such patients (1, 2). Although Aspergil-
lus fumigatus is responsible for the majority of IA, emerg-ing epidemiological reports have suggested an increase in the frequency of non-fumigatus isolates including A. 
flavus (3-7). Aspergillus flavus is the second most common 
Aspergillus spp. causing IA (2, 8). Until now, therapy for IA has been limited to azoles, echinocandins and polyenes. The use of voriconazole has improved the treatment of invasive aspergillosis. Voriconazole blocks ergosterol bio-synthesis by inhibiting the activity of 14-α-lanosterol de-methylase (CYP51A1), a cytochrome P450 enzyme involved in the conversion of lanosterol to 4,4-dimethylcholesta-8 (9),14,24-trien-3β-ol (9, 10). Voriconazole-resistant A. flavus was originally identified in a patient with IA, underlying a lung surgical operation (11). Recently, increasing Voricon-azole Resistance (VRC-R) in clinical isolates of Aspergillus spp. has been reported worldwide (2, 11).Based on limited studies, the most obvious mechanism 
of VRC-R in A. flavus involves overexpression or mutations of cyp51A (11, 12). Several studies have suggested that mul-tiple mechanisms unrelated to cyp51A undoubtedly exist. Furthermore, various studies from years 2006 to 2009 failed to detect genetic alterations within the cyp51A cod-ing sequence in 40% of triazole resistant Aspergillus spp. (1, 13-15). The primary mechanism responsible for azole resis-tance in clinical Candida isolates is overexpression of Mul-tidrug Resistance Efflux Pumps (MDR-EPs) (16, 17); upregu-lation of genes encoding MDR-EPs, contributing to triazole resistance in A. flavus have been previously described (18, 19). Two major classes of efflux proteins, the ATP-Binding Cassette (ABC) pumps and the Major Facilitator Superfam-ily (MFS) transporters have been shown to contribute to drug resistance (20-23).
2. ObjectivesThe present study was designed to evaluate the mRNA expression levels of cyp51A and mdr1 genes in voricon-
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azole resistant A. flavus by a Real-Time Reverse Transcrip-tase-Polymerase Chain Reaction approach.
3. Materials and Methods
3.1. Sampling and Susceptibility TestingForty-five A. flavus archived strains isolated by a pre-vious study were obtained from the Medical Mycology Laboratory, School of Public Health, Tehran University of Medical Sciences from January 2004 to December 2006. The Clinical and Laboratory Standards Institute (CLSI) M38-A3 microdilution method was used for assessment of the susceptibility of A. flavus strains to voriconazole (Ankleshwar [Gujarat], India). Candida krusei ATCC 6258 was used as a control strain for each plate (24, 25). All isolates were cultured on potato dextrose agar (Merck, Germany) at 35°C for seven days. Fresh conidial suspen-sions were collected and counted by hemocytometer; and the cell density was adjusted to 0.4 - 2.5 × 104 CFU/mL. Antifungal susceptibility testing was performed and Minimum Inhibitory Concentrations (MICs) were determined after 48 hours.
3.2. RNA Extraction and cDNA SynthesisStrains of A. flavus that demonstrated resistance to VRC as well as sensitive strains were selected for RNA extrac-tion. Conidia from each strain was inoculated in liquid culture (Merck, Germany) and incubated at 30°C with constant shaking at 120 rpm for 20 - 24 hours. Subse-quently, mycelia were collected at log-phase by filtration and washing thoroughly with sterile water. They were then frozen quickly in liquid nitrogen, and cell wall dis-rupted by pestle. Total RNA was extracted using the RNX-Plus Kit (Sinaclon, Iran). The quantity and quality of RNA were analyzed using nanodrop (ND-1000, Thermo Scien-tific Fisher, US). To avoid any genomic contamination, RNA was treated with DNase1 (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Treatment of total RNA with DNase1 improves the reliability of the quantitative method, considerably (26).cDNA synthesis was performed as previously described with some modifications (27, 28). Briefly, single stranded cDNA (ss-
cDNA) was synthesized using 6μg RNA, 20 pmol/μL random 
hexamer (Fermentas, Burlington, Canada), 20 pmol/μL oligo-dT (Fermentas, Burlington, Canada) and 10 mM of dNTP mix (Fermentas, Burlington, Canada), then incubated at 65°C for ten minutes followed by addition of 20 U Ribolock (Fermen-
tas, Burlington, Canada), 7.5 μL of 5X Reverse Transcriptase (RT) buffer (Fermentas, Burlington, Canada) and 200 U Mo-loney Murine Leukemia Virus (M-MuLV) reverse transcriptase enzyme (Fermentas, Burlington, Canada) and then incubated at 70°C for 10 minutes followed by incubation at 42°C for 60 minutes. cDNA was checked with ß tubulin (tubF 5′-GATG-GCTGCTTCTGACTTCC-3′, tubR 5′-GGTCGTTCATGTTGCTCTCA-3′) primers (designed by the Primer 3 online software version 0.4.0 and synthesized by the Bioneer company, Korea) as part 
of housekeeping with the following PCR conditions: five min at 94°C; 30 cycles of 30 seconds at 94°C, 30 seconds at 55°C, 45 seconds at 72 °C, and seven minutes at 72°C.
3.3. Real-Time Reverse Transcriptase-Polymerase 
Chain ReactionReal-time Reverse Transcriptase-PCR (RT-PCR) was car-ried out to determine the differences in expression pat-terns of identified genes between resistant and sensi-tive A. flavus isolates, using a CFX96™ Real-Time System (C1000TM Thermal Cycler) (Qiagen/Corbett Rotor-Gene 6000). In order to analyze the expression of cyp51A and 
mdr1 for voriconazole resistance in A. flavus, specific primers (Table 1) corresponding to the coding regions of cyp51A and mdr1 genes were designed by the Primer 3 online software version 0.4.0 (synthesized by Bioneer Korea). After cDNA synthesis, real-time RT-PCR was per-
formed in 20 μL reactions containing 1 μL cDNA target, 100 Nm forward and reverse primers and 1x SYBR Pre-mix Ex Taq™ (Takara, Tokyo, Japan). Experiments were conducted in triplicates. The PCR conditions were as follows: activation at 95°C for 30 seconds, amplification at 95°C for 5 seconds, 60°C for 30 seconds during 40 cycles. The relative value of the expression level of each gene was calculated by comparing the Cycle Thresh-olds (CTs) of the target genes with that of housekeep-ing genes (tub) using the 2 –ΔΔct method, as previously described (29).
3.4. In Silico StudyIn order to analyze the Protein-Protein Interactions (PPI) the Search Tool for the Retrieval of Interacting Genes/Pro-teins (STRING) database version 9.1 (http://stringdb. org/) was used. The predicted networks relied on physical and functional interactions of A. flavus.
4. Results
4.1. Drug Susceptibility of Aspergillus flavusFive out of 45 A. flavus tested isolates, according to the proposed interpretative breakpoints (24) with high MIC values in the presence of voriconazole, were defined as VRC resistant (Table 2).Three isolates, No 3, 4 and 5 were 
found to display the highest level of VRC-R (MIC, 16 μg/ml), whereas isolates 1 and 2 showed low levels of resistance. To verify the development of voriconazole resistance in the isolates, they were cultured on Sabouraud (SDA) agar containing progressively increasing concentrations of 
voriconazole (0.5 to 50 μg/ mL).
4.2. Cyp51A and mdr1 Expression in Aspergillus 
flavusFive VRC resistant of A. flavus were selected for qRT-PCR experiments to study mRNA expression of the cyp51A 
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and mdr1, a significant overexpression of cyp51A was found in four isolates (6.89 to 7.93 folds) (log2 P < 0.001) (Figure 1), whereas there was no significant expression of these gene in one.A variable expression of the mdr1 mRNA was detect-ed in four samples. Moderate and high levels of mdr1 mRNA was observed in isolate number 1 (4.77) and iso-lates number 2, 3 and 4 (10.94, 11.09 and 18.12 fold, re-spectively) (log2 P < 0.001).In contrast, isolate number 5 at the highest MIC, did not express mdr1 and cyp51A.
4.3. Predicting Protein Interactions in Aspergillus flavusTo determine which protein partners are implicated in the mechanism of A. flavus drug resistance by cyp51A and mdr1, we used the STRING database, as described in the materials and methods section. As shown in Figure 2, several important proteins were potentially associ-ated with the expressed genes obtained from the real-time PCR.
Table 1. Primer Sequences Used in This Study
Primer Sequence PCR Product 
Size, bp
CYP51AF 5′-ATGTCAATGCCGAGGAGAT-3′ 198
5′-AAGTTGGGGGATGTCTTGA-3′
MDR1F 5′-CTTTCCTGTCCACCGAGAC-3′ 178
5′-GAAGTACCCACAAGCCAGA-3′
Table 2. In Vitro Susceptibility of Laboratory Voriconazole-Resistant Aspergillus flavus Isolatesa,b
Isolate No. MIC, μg/mL of VCZ
Afl-VCZ1 2
Afl-VCZ2 4
Afl-VCZ3 16
Afl-VCZ4 16
Afl-VCZ5 16aAbbreviations: MIC, minimum inhibitory concentration; VCZ, voriconazole.bSusceptible ≤ 1 μg/mL, Intermediate: 2 μg/mL, Resistant : ≥ 4 μg/mL.
Figure 1. Assessment of mRNA Expression Levels of cyp51A and mdr1 genes
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Figure 2. Protein Interaction Network Prediction by STRING
The potential biological functions of the encoded proteins by cyp51A and mdr1 showed their possible role, which could depend on their interactions with a network of other cellular proteins. A, The highest-scoring interaction partners of cyp51A. As the confidence scores for these interactions are very high, more specific protein partners are shown. B, The interaction network of mdr1 display several protein partners.
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5. DiscussionIn the present study, we evaluated mRNA expression levels of cyp51A and mdr1 genes, in five A. flavus isolates. Both genes seemed to contribute to the development of drug resistance in the four resistant isolates. So far, differ-ent mechanisms have been reported for the resistance to azoles in A. flavus including genetic changes and/or over-expression of cyp51A, cyp51B and cyp51C as well as decreas-es in the concentration of intracellular drugs. The latter mechanism could be a consequence of either overexpres-sion of efflux pumps or due to reduction in drug penetra-tion (2, 11, 18, 19). The patterns of voriconazole resistance appear to differ in different cases. Various studies have demonstrated that point mutations in the cyp51A gene encoding 14-sterol demethylase could be a major mecha-nism accounting for triazole resistance in Aspergillus spp. (14, 30, 31). However, it has been shown that 40 - 70% of VRC-R A. flavus failed to demonstrate cyp51 mutations (19).Over the past decade, extensive studies attempted to overcome mdr, as one of the major challenges in drug resistance of fungi. Moreover, it is now clear that overex-pression of mdr1 has critical functions in human cancer treatment by reduction of the uptake and increasing the efflux of anti-cancer drugs (19). Our data demonstrated, a significant up regulation of cyp51A (6.89 to 7.93 folds) (P < 0.001) in four isolates, yetisolate number 5, at the highest MIC, did not express cyp51A and mdr1. It has been suggest-ed that up regulation in azole target enzyme gene cyp51A is associated with azole resistance in A. fumigatus and A. 
lentulus (10, 32). In contrary to these reports, Liu et al. in-dicated that the expression levels of the azole target en-zyme genes cyp51A, cyp51B and cyp51C were not associated with VRC resistance in A. flavus (2). However, their results are in disagreement with our findings (2).The lack of data showing an association between ABC or MFS multidrug efflux pumps and triazole resistance in Aspergillus, encouraged us to identify candidate efflux pumps that could be associated with azole resistance in 
A. flavus. In this regard, our data indicated significant dif-ferences in expression level of mdr1 between resistant and sensitive isolates. Moderate and high levels of mdr1 mRNA in four isolates mirrored MIC results with the ex-ception of the fifth isolate, which exhibited no expres-sion of mdr1 mRNA. Our results are in agreement with the report of Krishnan-Natesan et al. (11), which showed de-grees of MDR-EPs over expression in all VRC-R isolates of 
A. flavus; the level of MDR- EPs correlated with the degree of resistance as reflected by the MICs of the drugs. They also showed that there were no alterations in the cyp51A as well as MDR-EPs overexpression in some isolates.Co-regulation (co-expression and co-silencing) of mdr1 and cyp1A was reported in various human malignancies. Lampen et al. determined the co-induction of mdr1 and cyp1 genes in human Caco-2 intestinal cells on treatment with carcinogenic aromatic hydrocarbons (33). Finally, an in silico study was  performed using the online STRING 
program; in order to estimate the potential biological processes of genes that act in ergosterol biosynthesis and efflux pumps (EPs) function. Studies have shown that the majority of biological processes are regulated through association of protein molecules. In addition, functional units of cells are often complex assemblies of several macromolecules, where proteins play a vital role. Therefore, protein–protein interaction networks play an important role in the organization of an organism’s life.At the highest confidence score, erg1, erg3 and erg28 Lanosterol synthase proteins were predicted to interact either directly or indirectly with the cyp51A (erg11) pro-tein. Furthermore, Erg1 catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway. The interac-tion of erg1 seems to be crucial for sterol biosynthesis. As shown in Figure 2, ABC a-pheromone efflux pump atrD, is directly or indirectly potentially associated with the 
mdr1. Furthermore, atrD as the efflux protein removes drug accumulated in the cell with the expense of energy and reduces the concentration of drug required for the inhibition of growth. The in silico results predicted that voriconazole resistance could be mediated through cooperation of protein partners interaction. Taken to-gether, our experimental and in silico findings may pro-vide new insight into the complex molecular pathways in drug resistance and could assist design an efficient therapeutic strategy for aspergillosis.Our data suggested that there are different scenarios that explain the biological significance of the expression of mdr1 and cyp51A in drug resistance, at least for our lim-ited samples. There are two hypotheses: 1) Mdr1 protein regulates cyp51A mRNA expression via a positive domi-nant effect. This hypothesis comes from our findings, which showed that in the absence of mdr1, we could not detect cyp51A mRNA expression. The lack of mdr1 expres-sion could have occurred due to gene deletion or other genetic and epigenetic phenomena. 2) Several unknown genes, loci and molecular pathways could play central roles in the development of drug resistance, which is known as a complex trait. Consequently, it is quite under-standable that in the absence of cyp51A and mdr1 in isolate number 5, the aforementioned mechanisms might have been implicated in the drug resistance. Collectively, the above observations suggest that cyp51A and mdr1, other genes and loci are responsible for voriconazole resistance in A. flavus. These data suggested that more investigation should be done on larger samples.
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